Lilly acquires VS Keystone partnership! RET inhibitor son market is full of gunpowder!

On May 8, the U.SFood and Drug Administration (FDA) announced that it has approved ret inhibitor Retevmo (selpercatinib) developed by Eli Lilly's subsidiary Loxo Oncology for the treatment of non-small cell lung cancer (NSCLC), myeloid thyroid cancer (MTC) and thyroid cancer developed by Loxo OncologyRetevmo is the first treatment specifically for cancer patients with RET gene mutationsRetevmo has previously been granted fda-awarded ground-breaking therapeutics and orphan drug qualifications, and its application for new drugs has also been qualified for priority reviewthe RET gene is located on the long arm of chromosome 10 and encodes a receptor tyrosine kinaseExpression sympathic in normal neurons, sympathetic and parasympathetic nerve sections, thyroid C cells, adrenal myelin cells, genitourinary cells, and testicular reproductive cellsWhen reT protein is activated, it activates downstream signaling pathways (including RAS, MAPK, ERK, PI3K, AKT, etc.), leading to cell proliferation, migration, and differentiationActivation mutations in the RET gene are associated with malignant tumors in humans, but if the RET gene loses its function, it can also lead to very gastrointestinal developmental diseases, such as congenital megacolonsRetevmo (selpercatinib, formerly known as LOXO-292) is a selective reT kinase inhibitorRetevmo can affect tumor cells and healthy cells, which can produce side effectsRetevmo is an oral prescription drug that takes a total of 120 mg or 160 mg twice a day, depending on the weight (-/50 kg) until the condition worsens or is of unacceptable toxicityPicture Source: LillyThe FDA approval is based on the results of a clinical trial in which Retevmo treats three types of cancerIn 105 adult patients with RET fusion-positive NSCLC who had previously received chemotherapy for platinum-type drugs, the objective remission rate (ORR) was 64%In patients receiving remission, 81% had a duration of at least 6 monthsThe trial also evaluated the efficacy of 39 patients with primary RET fusion-positive NSCLCThe ORR in these patients was 84% The duration of remission was at least 6 months in 58% of patients who received remission In adults and children with RET mutations at age 12 and older, 55 treated patients had ORR of 69% and 76% of patients with remission had a duration of at least 6 months Of the 88 first-treatment patients, THE ORR was 73% and 61% of the patients who received remission lasted at least 6 months the American Society for Cancer Research (AACR) in 2014 proposed innovative clinical trials for precision cancer medicine that could be divided into two broad categories, Basket Trial and Umbrella Trial The former image points out that a targeted drug is a basket, putting different cancers with the same target gene into a basket for research is a basket test, "Basket Trial" is essentially a drug to deal with different tumors, and RET inhibitors are part of the Basket test Pralsetinib (BLU-667), also a RET inhibitor, was developed by Blueprint Medicines Earlier this year, Blueprint Medicines launched a rolling filing with the U.S Food and Drug Administration (FDA) for a new drug application (NDA) for The RET-positive NSCLC patient In 2018, Keystone Pharmaceuticals reached an agreement with Blueprint Medicines, which obtained exclusive development and commercialization of Pralsetinib in Chinese mainland, Hong Kong, Macau and Taiwan, completed its first Chinese patient administration in Phase I registered trials last year data source: Blueprint Medicines With Retevmo's approval and Pralsetinib filing an application, the competition for the two RET inhibitors has entered the white heat phase Their former LOXO-292 and BLU-667 were the focus of attention, and now Retevmo is the first to be approved, and what will be the competition for the ret inhibitor market in the future? Is Retevmo a bully? Or is Pralsetinib coming out? Or are new competitors emerging? We'll see reference source: 1, FDA First First For Patients With Lung and Thyroid Cancer s With A Certain Genetic Genetic Genetic Or Fusion 2, RET gene mutation and targeted drug 3, 2019 CSCO New RET Inhibitor S Pancancer therapy Frontier Progress!